Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. (NWBO) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Northwest Biotherapeutics, Inc. (NWBO), covering cash flow, earnings, and balance sheets.
Northwest Biotherapeutics, Inc. (NWBO) Income Statement & Financial Overview
Analyze Northwest Biotherapeutics, Inc.’s NWBO earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $375000.00 | $231000.00 | $357000.00 | $510000.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $375000.00 | $231000.00 | $357000.00 | $510000.00 |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $8.35M | $10.52M | $8.13M | $8.29M |
| SG&A Expenses | $9.34M | $8.21M | $7.03M | $9.68M |
| Operating Expenses | $17.69M | $18.73M | $15.16M | $17.97M |
| Total Costs & Expenses | $17.69M | $18.73M | $15.16M | $17.97M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.60M | $2.49M | $2.08M | $1.68M |
| Depreciation & Amortization | $0.00 | $501000.00 | $522000.00 | $516000.00 |
| EBITDA | -$17.31M | -$25.23M | -$16.77M | -$15.67M |
| EBITDA Ratio | -$46.16 | -$109.24 | -$46.98 | -$30.73 |
| Operating Income | -$17.31M | -$18.50M | -$14.80M | -$17.46M |
| Operating Income Ratio | -$46.16 | -$80.08 | -$41.46 | -$34.24 |
| Other Income/Expenses (Net) | -$2.30M | -$9.72M | -$4.57M | -$405000.00 |
| Income Before Tax | -$19.61M | -$28.22M | -$19.37M | -$17.87M |
| Income Before Tax Ratio | -$52.29 | -$122.18 | -$54.27 | -$35.04 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$19.61M | -$28.22M | -$19.37M | -$17.87M |
| Net Income Ratio | -$52.29 | -$122.18 | -$54.27 | -$35.04 |
| EPS | -$0.01 | -$0.02 | -$0.02 | -$0.02 |
| Diluted EPS | -$0.01 | -$0.02 | -$0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $1.36B | $1.24B | $1.26B | $1.21B |
| Weighted Avg Shares Outstanding (Diluted) | $1.36B | $1.24B | $1.26B | $1.21B |
The company's financials show resilient growth, with revenue advancing from $510000.00 in Q2 2024 to $375000.00 in Q1 2025. Gross profit remained healthy with margins at 100% in Q1 2025 compared to 100% in Q2 2024. Operating income hit -$17.31M last quarter, sustaining a consistent -4616% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$17.31M. Net income rose to -$19.61M, while earnings per share reached -$0.01. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan